The DOI matches its Crossref record.
Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.
Open accessAbstract
An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), is a major target of T cells in lesions of multiple sclerosis (MS) and in experimental allergic encephalomyelitis (EAE). T cells found in EAE lesions bear the same amino acids in the third complementary determining region of the T cell receptor (TCR) as those found in MS lesions. We analyzed the trimolecular interactions between MBP p87-99, class II major histocompatibility complex (MHC), and TCR, and designed soluble inhibitors for therapy. F, N, I, and V at positions 90, 92, 93, and 94 interact with MHC, whereas K, T, and P at positions 91, 95, and 96 interact with TCR. The peptides, p87-99[95T > A] and p87-99[96P > A] could compete more effectively with p87-99 for binding to MHC and could antagonize the in vitro response to T cells to p87-99 more effectively than p87-99[91K > A]. However, only p87-99[91K > A] prevented and reversed EAE, indicating that the extent of MHC or TCR competition does not predict success in treating EAE. To elucidate the mechanism of inhibition of EAE, draining lymph node cells from rats immunized with the native peptide alone or together with each of the three TCR antagonists were challenged in vitro with p87-99. Administration of p87-99[91K > A], but not p87-99 [95T > A] or p87-99[96P > A], reduced the production of tumor necrosis factor (TNF)- alpha and interferon (IFN) gamma. IFN-gamma and TNF-alpha are two cytokines that are critical in the pathogenesis of EAE and MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System
Steinman, M. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81107-1 · Cited by 903
Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Kohm, A. P., Carpentier, P. A., Anger, H. A., & Miller, S. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4712 · Cited by 782
Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L., Comi, G., Kappos, L., Oger, J., et al. (2000) · Nature Medicine · doi:10.1038/80525 · Cited by 512
Self-citationSteinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Self-citationDuda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8970 · Cited by 416
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
Brocke, S., Gijbels, K., Allegretta, M., Ferber, I., Piercy, C., Blankensteini, T., Martin, R., Utz, U., Karin, N., Mitchell, D., et al. (1996) · Nature · doi:10.1038/379343a0 · Cited by 379
Self-citationPeptide-based therapeutic vaccines for allergic and autoimmune diseases
Larché, M., & Wraith, D. C. (2005) · Nature Medicine · doi:10.1038/nm1226 · Cited by 326
Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease
Miller, S. D., Turley, D. M., & Podojil, J. R. (2007) · Nature Reviews Immunology · doi:10.1038/nri2153 · Cited by 290
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
Steinman, L., & Zamvil, S. S. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.014 · Cited by 265
Self-citationSong, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Metadata
- Authors
- Karin, N., Mitchell, D. J., Brocke, S., Ling, N., & Steinman, L.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-12-01
- Volume
- 180
- Issue
- 6
- Pages
- 2227-2237
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2163433446
- Cited by
- 211
- References
- 0
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.